Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2024-03-25 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于使用部分闲置募集资金现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the use of part of idle raised funds for cash management. It details the board meeting approval, the amount and purpose of the cash management, risk analysis, and compliance with regulatory requirements. The document is a formal disclosure about the company's financing fund usage and cash management activities, not a financial report or audit. It is not an annual or interim report, earnings release, or management discussion. It is a regulatory announcement about capital usage and cash management related to raised funds. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 4183 characters, which is consistent with an announcement rather than a full report.
2024-03-25 Chinese
2023年年度非经营性资金占用及其他关联资金往来情况汇总表
Regulatory Filings Classification · 95% confidence The document is a summary table detailing the non-operating fund occupation and other related party fund transactions for the year 2023 by Shenzhen Salubris Pharmaceuticals Co., Ltd. It includes financial figures such as beginning balances, cumulative amounts, interest, repayments, and ending balances for various related parties. The document is relatively short (1534 characters) and appears to be a specific financial disclosure related to related party transactions rather than a full financial report. It does not contain comprehensive financial statements or management discussion but is a regulatory disclosure of related party fund usage. This type of document fits best under Regulatory Filings (RNS), as it is a compliance disclosure that does not qualify as a full Annual Report, Interim Report, or Audit Report, nor is it an announcement or presentation. Therefore, the classification is RNS with high confidence.
2024-03-25 Chinese
第六届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of the 2023 Annual Report, the Supervisory Board's work report, profit distribution plan, internal control self-assessment report, and other related matters. It mentions that these reports will be submitted to the 2023 Annual General Meeting for approval and provides links to where the full reports can be found. The document itself does not contain the full annual report or detailed financial statements but rather summarizes the resolutions and approvals made by the Supervisory Board. The document length is 4236 characters, which is relatively short and consistent with an announcement rather than the full report. Therefore, according to the "Menu vs Meal" rule, this document is an announcement of the report and related resolutions, not the full Annual Report (10-K). It fits best under Regulatory Filings (RNS) as a general regulatory announcement about supervisory board resolutions and report approvals.
2024-03-25 Chinese
关于会计师事务所2023年度履职情况的评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the accounting firm (auditor) for the year 2023. It details the auditor's qualifications, independence, quality control, audit procedures, and compliance with professional standards. It does not contain the company's financial statements or results but rather assesses the auditor's work related to the annual audit. This fits the definition of an Audit Report / Information (AR), which includes standalone audit reports and related information about audit quality and procedures, excluding the full Annual Report. The document length is 3154 characters, which is consistent with a detailed audit evaluation report rather than a brief announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-03-25 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2023 年度内部控制评价报告' which translates to '2023 Annual Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2023. The content includes detailed descriptions of internal control scope, evaluation criteria, defect classifications, and conclusions about the effectiveness of financial and non-financial internal controls. It is a standalone report focused on internal control evaluation rather than a full annual report or audit report. The document length is 3146 characters, which is relatively short but contains substantive evaluation content rather than just an announcement or certification. This type of report aligns with an Audit Report / Information (AR) category, as it is a standalone internal control evaluation report, not the full annual report (10-K) or a simple announcement. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-03-25 Chinese
董事会审计委员会对2023年度年审会计师履行监督职责情况的报告
Audit Report / Information Classification · 95% confidence The document is a report from the Board Audit Committee regarding the supervision of the external auditor's duties for the fiscal year 2023. It discusses the auditor's qualifications, the audit process, and the committee's evaluation of the auditor's performance. The document references the 2023 annual audit but does not contain the full annual report or financial statements itself. It is a standalone audit-related report focusing on the audit committee's oversight and the auditor's work, which fits the definition of an Audit Report / Information (AR). The document length is 2037 characters, which is relatively short but contains substantive content about audit supervision rather than just an announcement or certification. Therefore, it is classified as AR with high confidence. FY 2023
2024-03-25 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.